Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints Peter Theil head of non-clinical development

He joins the Belgium pharma company from Genentech

Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.

He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.

At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.

UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.

Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.

McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics